2 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Recruiting 2, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 5 | Recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1 |
Follow Tolerability: new trials by email Literature Review of Tolerability trials Research Report on Tolerability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors Test Product HY07121 - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 258 | 2024-10-24 | 2026-10-13 |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation Test product: HYP-2090PTSA - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 257 | 2024-02-04 | 2026-01-29 |
| Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors IPG7236 - Safety Issues, Tolerability | Phase 1 / Phase 2 | Completed | Nanjing Immunophage Biotech Co., Ltd | 34 | 2021-11-15 | 2026-07-08 |
| TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms MDG1011, Investigator Choice therapy - Safety, Tolerability | Phase 1 / Phase 2 | Terminated | Medigene AG | 9 | 2018-03-27 | 2023-02-15 |
| Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study Moxifloxacin - Meningitis, Tuberculous, Pharmacokinetics | Phase 2 | Completed | Universitas Padjadjaran | 60 | 2010-10-01 | 2012-06-07 |
Actinomycetales Infections (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Central Nervous System Bacterial Infections (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Gram-Positive Bacterial Infections (1) · Infections (1) · Meningitis (1) · Meningitis, Bacterial (1) · Mycobacterium Infections (1) · Nervous System Diseases (1) · Neuroinflammatory Diseases (1) · Tuberculosis (1) · Tuberculosis, Central Nervous System (1)
Injections (1) · Injections, Subcutaneous (1) · Moxifloxacin (1)
Sichuan Huiyu Pharmaceutical Co., Ltd (3) · Medigene AG (1) · Nanjing Immunophage Biotech Co., Ltd (1) · Universitas Padjadjaran (1)
China (3) · Germany (1) · Indonesia (1) · United States (1)
Rovina Ruslami, PhD (1) · Simone Thomas, PD Dr. med. (1)